Kobayashi, Toshinori http://orcid.org/0000-0001-8042-5073
Matsui, Yuki
Miki, Hisanori
Hatta, Masahiko
Ishida, Mitsuaki
Satake, Hironaga http://orcid.org/0000-0001-7629-6803
Sekimoto, Mitsugu
Article History
Received: 7 October 2022
Accepted: 22 January 2023
First Online: 3 February 2023
Declarations
:
: This study was approved by the Institutional Review Board of Kansai Medical University Hospital (approval no. #2021108). Informed consent was obtained from the patients via the opt-out method, owing to the study’s retrospective design, with no risk to the participants.
: Consent was obtained from the patient to publish the clinical and imaging data in this report.
: Hironaga Satake received research funding from Ono Pharmaceutical Co., Ltd., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Sanofi; honoraria from Bayer Co., Ltd.; Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd., and Yakult Honsha Co., Ltd.The other authors disclose no conflict of interest related to the content of this report.